Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study.

Journal of Alzheimer's disease : JAD - 1 Feb 2025

Yang Hao, Ning Yuye, Chen Meilin, Jia Jianping

Abstract excerpt

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors is a novel category of medications for diabetes, exhibiting neuroprotective potential. However, evidence regarding whether the use of SGLT2 inhibitors effectively reduces the risk of Alzheimer's disease (AD) remains unclear. OBJECTIVE: Our study employed Mendelian randomization (MR) analysis to investigate potential causal relationships between SGLT2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Biomarkers
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Treatment and Management

Share to Genetic Associations and Epidemiology

Share to Glycated Hemoglobin

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 39834250
DOI: 10.1177/13872877241309674

Genes

SLC5A2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study.PMID 39834250Read ↗

Sodium-glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study.Semantic proximity Read ↗

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.Semantic proximity Read ↗

The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization StudySemantic proximity Read ↗

SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study.Semantic proximity Read ↗

Investigating Causal Relations Between Circulating Metabolites and Alzheimer's Disease: A Mendelian Randomization Study.Semantic proximity Read ↗

Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization studySemantic proximity Read ↗

Investigating Causal Relations Between Circulating Metabolites and Alzheimer’s Diseases: A Mendelian Randomization StudySemantic proximity Read ↗

SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.Semantic proximity Read ↗

Causal effects of serum metabolites on amyotrophic lateral sclerosis: A Mendelian randomization study.Semantic proximity Read ↗

Risk of Alzheimer's disease and genetically predicted levels of 1400 plasma metabolites: a Mendelian randomization study.Semantic proximity Read ↗

Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization StudySemantic proximity Read ↗

Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.